Eloxx Pharmaceuticals, Inc. has acquired Zikani Therapeutics, Inc. in an all-stock transaction, combines complementary ribosomal RNA-targeted genetic therapy platforms and therapies for the treatment of rare diseases and oncology. Sumit Aggarwal, previously the President and Chief Executive Officer of Zikani, has been named President and Chief Executive Officer of Eloxx, and Vijay Modur, M.D., Ph.D., who was Zikani’s Chief Scientific and Medical Officer, has been named Eloxx’s Head of R&D. ...